$IMRX earnings report

Immuneering reports Q3 2026 net loss of $(24,192,583) with no revenue, extends Phase 2 pancreatic follow-up, expands Phase 3 enrollment target to approximately 570 patients, and guides cash runway into Q4 2028. AlphAI read Immuneering's Q3 FY2026 filing as mixed.

Q3 FY2026

AlphAI · Earnings readIMRX · Q3 2026 · ended 2026-09-30

Immuneering reports Q3 2026 net loss of $(24,192,583) with no revenue, extends Phase 2 pancreatic follow-up, expands Phase 3 enrollment target to approximately 570 patients, and guides cash runway into Q4 2028

→Mixed quarter

The filing reports no revenue line and a wider net loss, with R&D up from $10,867,983 to $20,721,243 and cash and marketable securities down from $217.0 million to $166.1 million. Clinical and enrollment updates are positive and the company extended its cash runway guidance to Q4 2028, but the filing does not provide prior runway guidance or prior-quarter results, so the direction of the guide cannot be confirmed from the documents.

EPS · GAAP
$(0.37)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses, Q3 2026GAAP$20,721,243––
General and administrative expenses, Q3 2026GAAP$5,059,459––
Amortization of intangible asset, Q3 2026GAAP7,317––
Total operating expenses, Q3 2026GAAP25,788,019––
Loss from operations, Q3 2026GAAP$(25,788,019)––
Interest income, Q3 2026GAAP1,204,598––
Other income, net, Q3 2026GAAP390,838––
Net loss attributable to common stockholders, Q3 2026GAAP$(24,192,583)––
Net loss per share, basic and diluted, Q3 2026GAAP$(0.37)––
Comprehensive loss, Q3 2026GAAP$(24,335,496)––
Research and development expenses, nine months 2026GAAP$45,363,112––
General and administrative expenses, nine months 2026GAAP$14,738,398––
Amortization of intangible asset, nine months 2026GAAP21,950––
Total operating expenses, nine months 2026GAAP60,123,460––
Loss from operations, nine months 2026GAAP$(60,123,460)––
Interest income, nine months 2026GAAP3,647,786––
Other income, net, nine months 2026GAAP1,551,769––
Net loss attributable to common stockholders, nine months 2026GAAP$(54,923,905)––
Net loss per share, basic and diluted, nine months 2026GAAP$(0.85)––
Comprehensive loss, nine months 2026GAAP$(55,554,390)––
Cash, cash equivalents and marketable securities at September 30, 2026other$166.1M––

Cash runway as of September 30, 2026 outlook

  • NoteCash runway expected to be sufficient to fund operations into the fourth quarter of 2028, reflecting the Phase 2 trial extension, accelerated and expanded Phase 3 enrollment, and commercial readiness activities

Capital returns

  • No share repurchases or dividends are reported in the filing.

What drove it

  • The company attributes the increase in R&D expenses to higher clinical costs related to its lead program and increased personnel to support ongoing research and development activities.
  • The company attributes the increase in G&A expenses to higher stock-based compensation costs and employee-related costs in connection with general and administrative functions.
  • The filing reports the Phase 2 pancreatic cancer follow-up was extended because patients are living longer than projected.
  • The company states that enrollment in the Phase 3 MAPKeeper 301 trial is ahead of schedule, and that the enrollment target is expanding from 510 to 570 patients.

Concerns

  • No revenue line is reported; the company's results consist of operating expenses and other income.
  • Loss from operations rose from $(15,380,706) to $(25,788,019) in the quarter as R&D expenses increased.
  • Cash, cash equivalents and marketable securities declined from $217.0 million at December 31, 2025 to $166.1 million at September 30, 2026.
  • Total stockholders' equity declined from $218,483,968 to $168,680,697 over the same period.
  • The filing does not report operating cash flow, so the cash consumption from operations cannot be read from the documents.

What to watch

  • 4Q 2026 (SITC): preclinical data for atebimetinib in combination with anti-PD-1 in lung cancer.
  • 4Q 2026: first patient dosed in the Phase 2 atebimetinib + anti-PD-1 (cemiplimab) lung cancer trial.
  • 1H 2027: updated 1L PDAC Phase 2 atebimetinib + mGnP data (N=55).
  • Mid-2027: start of IND-enabling studies for the next DCI product candidate program.
  • Late-2027: preliminary data readout from the Phase 2 lung cancer trial.
  • Mid-2028: topline data readout from the MAPKeeper 301 trial, which the company says it may accelerate.
  • Cash runway guidance into the fourth quarter of 2028.

Balance sheet and cash flow

  • Cash, cash equivalents and marketable securities were $166.1 million at September 30, 2026, compared with $217.0 million at December 31, 2025.
  • Cash and cash equivalents: $58,226,805 at September 30, 2026 vs $128,645,025 at December 31, 2025.
  • Marketable securities, current: $87,178,645 at September 30, 2026 vs $44,186,244 at December 31, 2025.
  • Marketable securities, non-current: $20,712,253 at September 30, 2026 vs $44,183,186 at December 31, 2025.
  • Total assets: $182,561,047 at September 30, 2026 vs $231,985,010 at December 31, 2025.
  • Total liabilities: $13,880,350 at September 30, 2026 vs $13,501,042 at December 31, 2025.
  • Total stockholders' equity: $168,680,697 at September 30, 2026 vs $218,483,968 at December 31, 2025.
  • Accumulated deficit: $(335,243,989) at September 30, 2026 vs $(280,320,084) at December 31, 2025.
  • The filing reports no debt balance and no cash flow statement.

Analysis

Immuneering reported a third-quarter 2026 net loss attributable to common stockholders of $(24,192,583), or $(0.37) per share, against $(14,964,875), or $(0.38) per share, in the third quarter of 2025. The filing contains no revenue line. Total operating expenses rose to 25,788,019 from 15,380,706, led by R&D expenses of $20,721,243 against $10,867,983 a year earlier. The company attributes the R&D increase to higher clinical costs for its lead program and to increased personnel. G&A expenses rose to $5,059,459 from $4,505,406, which the company attributes to stock-based compensation and employee-related costs. Interest income increased to 1,204,598 from 415,831 in the quarter, and other income, net was 390,838, which partly offset the operating loss at the net line.

For the nine months ended September 30, 2026, the net loss was $(54,923,905), or $(0.85) per share, compared with $(44,444,888), or $(1.20) per share, a year earlier. The per-share loss narrowed while the absolute loss widened, and the weighted-average share count rose from 37,077,041 to 64,690,275 for the nine months, which the filing does not explain beyond the share count itself. Comprehensive loss for the nine months was $(55,554,390), including an unrealized loss on marketable securities of (630,485).

The balance sheet shows cash, cash equivalents and marketable securities of $166.1 million at September 30, 2026, against $217.0 million at December 31, 2025. Total assets fell to $182,561,047 from $231,985,010, and total stockholders' equity fell to $168,680,697 from $218,483,968. The filing reports no debt. The company updated its cash runway guidance to the fourth quarter of 2028, which it ties to the Phase 2 extension, accelerated and expanded Phase 3 enrollment and commercial readiness activities. The filing does not state the prior runway guidance, so whether the runway was extended cannot be determined from these documents.

Clinical attention centers on three items. The Phase 2 mGnP arm (N=55) follow-up has been extended because patients are living longer than projected, with an update now expected in 1H 2027. The Phase 3 MAPKeeper 301 enrollment target expands from 510 to 570 patients, and the company says enrollment is ahead of schedule and could accelerate the mid-2028 topline readout. Those statements are the company's own forward-looking estimates and are not yet reflected in reported results. The company also cites presentations at the 2026 AACR Conference on Pancreatic Cancer and ESMO Congress 2026, and a Cancer Research publication.

The quarter's read depends on the balance between a clinical-stage cost base that is rising and a cash balance that is falling, against positive trial-timing updates. The filing does not include operating cash flow, prior-quarter figures or prior guidance, so cash burn per period and the change in guidance cannot be measured from the documents.

Management, verbatim

The 17.3 months median overall survival with excellent tolerability that we reported at ASCO is unprecedented among agents targeting this pathway, and we are excited to share updated clinical data in the first half of 2027.

Ben Zeskind, Ph.D., CEO

We have updated our cash runway guidance to the fourth quarter of 2028 to reflect our Phase 2 extension, accelerated and expanded Phase 3 enrollment, and commercial readiness activities.

Ben Zeskind, Ph.D., CEO

Not in the filing

stated, not guessed
  • No revenue or collaboration revenue line is reported in the filing.
  • Year-over-year and quarter-over-quarter percentage changes are not printed for any metric.
  • Prior-quarter (Q2 2026) results are not provided.
  • Operating cash flow, investing cash flow and free cash flow are not reported.
  • Prior cash runway guidance is not stated, so a change in guidance cannot be confirmed.
  • Cash, cash equivalents and marketable securities at December 31, 2025 are printed only as a point-in-time balance and not as a prior-year period figure.
  • No share repurchase or dividend activity is reported.
  • No consensus estimates or share-price reaction are provided in the documents.
  • Previous release outlook was not provided, so vs_prior_guidance is empty.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about IMRX earnings dates

When is Immuneering's next earnings date?
AlphAI has no date for IMRX yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.